Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma

Fig. 5

Bcl-2 dependent tumors that recur following ABT-199 therapy maintain Bcl-2 dependence patterns in vivo. 2/9 Bcl-2 dependent tumors treated with ABT-199 + CPM completely regressed but then regrew. a One mouse received a second round of ABT-199 + CPM therapy (14 days) that led to a second complete regression of the tumor out to 50 days post second treatment. b The other mouse was sacrificed so that the recurrent tumor could be profiled for Bcl-2 dependence patterns by co-IP. Co-IP showed that the xenograft maintained Bim bound to Bcl-2 despite its recurrence. These results suggest that the short duration of treatment led to these two tumor’s growing back

Back to article page
\